Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma

Ns, Lai; Dg, Wu; Xg, Fang; Lin, Yingsong; Ss, Chen; Zb, Li; Xu, Shisan

doi:10.1038/bjc.2015.91

Cited by 145 publications

(108 citation statements)

References 45 publications

(56 reference statements)

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…Subsequently, we assessed the remaining 254 full‐text articles and excluded 226 studies based on the exclusion criteria, including 30 meetings, and 196 without clinical data to make a 2 × 2 contingency table. In total, 28 studies were ultimately included in this study . A flowchart of the selection process for this study is presented in Figure .…”

Section: Resultsmentioning

confidence: 99%

MicroRNAs as potential biomarkers for the diagnosis of glioma: A systematic review and meta‐analysis

et al. 2018

View full text Add to dashboard Cite

Glioma is the most common central nervous system tumor and associated with poor prognosis. Identifying effective diagnostic biomarkers for glioma is particularly important in order to guide optimizing treatment. MicroRNAs (miRNAs) have drawn much attention because of their diagnostic value in diverse cancers, including glioma. We summarized studies to identify the potential diagnostic values of miRNAs in glioma patients. We included articles reporting miRNAs for differentiation of glioma patients from controls. We calculated sensitivities, specificities, and area under the curves (AUC) of individual miRNA and miRNA panels. We found that overall sensitivity, specificity, and AUC of miRNAs in diagnosis of glioma were 85% (95% confidence interval [CI]: 0.81‐0.89), 90% (95% CI 0.85‐0.93), and 93% (95% CI 0.91‐0.95), respectively. Meta‐regression analysis showed that the detection of miRNAs expression in cerebrospinal fluid (CSF) and brain tissue largely improved the diagnostic accuracy. Likewise, panels of multiple miRNAs could enhance the pooled sensitivity. Moreover, AUC of miR‐21 was 0.88, with 86% sensitivity and 94% specificity. This study demonstrated that miRNAs could function as potential diagnosis markers in glioma. Detection of miRNAs in CSF and brain tissue displays high accuracy in the diagnosis of glioma.

show abstract

Section: Resultsmentioning

confidence: 99%

MicroRNAs as potential biomarkers for the diagnosis of glioma: A systematic review and meta‐analysis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…) and glioma (Lai et al . ). Consequently, it has some limitations with regard to the role of miR‐210 in detection and assessment of different types of cancers.…”

Section: Discussionmentioning

confidence: 97%

Circulating miR-210 as a diagnostic and prognostic biomarker for colorectal cancer

Wang

Liu

et al. 2016

Eur J Cancer Care

View full text Add to dashboard Cite

microRNA-210 (miR-210), the master hypoxamir, is overexpressed and generally exhibits oncogenic properties in most human solid tumours, including colorectal cancer (CRC). However, the status of circulating miR-210 in CRC is still unknown. This study aims to assess the clinical significance of circulating miR-210 in CRC. Using (reverse transcription quantitative PCR) RT-qPCR analysis, we compared the expression levels of circulating miR-210 in serum of 268 CRC patients and 102 healthy controls, and found that serum miR-210 was significantly higher in CRC than in healthy controls (P < 0.001). The area under the receiver operating characteristic curve (AUC) of circulating miR-210 to detect CRC was 0.821, with a sensitivity of 74.6% and a specificity of 73.5%. The AUC of circulating miR-210 showed significantly higher detection capability than that of carcinoembryogenic antigen (P < 0.05). Kaplan-Meier analysis demonstrated that increased serum miR-210 level correlated with reduced overall survival (OS) and disease-free survival (DFS) (P = 0.008 and P = 0.008 respectively). Cox analysis indicated circulating miR-210 was an independent prognostic factor for OS and DFS. Taken together, our data suggested that circulating miR-210 could be a potential non-invasive marker for diagnosis and prognosis of CRC.

show abstract

“…Moreover, miRNAs may be promising candidates as biomarkers for early cancer diagnosis and prognosis and for the modification of responses to anticancer treatment. 41, 42, 43, 44 Because the hypermethylation and downregulation of miR-506 were associated with poor prognoses, miR-506 has a strong potential for use as a biomarker for improved management of pancreatic cancer.…”

Section: Discussionmentioning

confidence: 99%

Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB signaling

et al. 2016

Oncogene

144

112

View full text Add to dashboard Cite

The aberrant expression of microRNAs (miRNAs) has emerged as an important hallmark of cancer. However, the molecular mechanisms underlying the changes in miRNA expression remain unclear. In this study, we discovered a novel epigenetic mechanism of miR-506 regulation and investigated its functional significance in pancreatic cancer. Sequencing analysis revealed that the miR-506 promoter is highly methylated in pancreatic cancer tissues compared with non-cancerous tissues. Reduced miR-506 expression was significantly associated with clinical stage, pathologic tumor status, distant metastasis and decreased survival of pancreatic cancer patients. miR-506 inhibited cell proliferation, induced cell cycle arrest at the G1/S transition and enhanced apoptosis and chemosensitivity of pancreatic cancer cells. Furthermore, we identified sphingosine kinase 1 (SPHK1) as a novel target of miR-506, the expression of which inhibited the SPHK1/Akt/NF-κB signaling pathway, which is activated in pancreatic cancer. High SPHK1 expression was significantly associated with poor survival in a large cohort of pancreatic cancer specimens. Our data suggest that miR-506 acts as a tumor suppressor miRNA and is epigenetically silenced in pancreatic cancer. The newly identified miR-506/SPHK1 axis represents a novel therapeutic strategy for future pancreatic cancer treatment.

show abstract

Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma

Cited by 145 publications

References 45 publications

MicroRNAs as potential biomarkers for the diagnosis of glioma: A systematic review and meta‐analysis

MicroRNAs as potential biomarkers for the diagnosis of glioma: A systematic review and meta‐analysis

Circulating miR-210 as a diagnostic and prognostic biomarker for colorectal cancer

Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB signaling

Contact Info

Product

Resources

About